Varvara Ryabkova
1 
, Anna Bregovskaya
2 , Lidiia Soprun
1,3 , Natalia Gavrilova
1,3,4* , Leonid P. Churilov
1,4 1 St. Petersburg State University, Laboratory of the Mosaic of Autoimmunity, 199034, Universitetskaya Emb., 7-9-11, St. Petersburg, Russia
2 Almazov National Medical Research Centre, 197341, Akkuratova str., 2, St. Petersburg, Russia
3 St. Petersburg State University Hospital, 190103, Fontanka river Emb., 154, St. Petersburg, Russia
4 St. Petersburg Research Institute of Phthisiopulmonology, 191036, Ligovskii pr., 2-4, St. Petersburg, Russia
*Corresponding Author: St. Petersburg Research Institute of Phthisiopulmonology, 191036, Ligovskii pr., 2-4, St. Petersburg, Russia Email n.y.gavrilova@spbu.ru
Abstract
In 2020, the world suffered an epidemic of a new coronavirus infection, after which it became obvious that the consequences of this disease persist for a long time after the recovery, perhaps, for several months. This complication was called post-COVID-19 syndrome and was recognized by the World Health Organization, which was reflected in the Delphi Consensus on October 6, 2021. The clinical characteristics of this disease include a significant number of immunological manifestations, including fever, arthralgia, myalgia, flu-like symptoms, as well as autoimmune diseases manifestation. These symptoms may allude the autoimmune genesis of the COVID-19 complications. This mini-review summarizes the current understanding of the systemic manifestations of COVID-19 and the possible role of impaired immune function in the pathogenesis of post-COVID-19 syndrome.
Keywords: COVID-19, post-COVID-19 condition, SARS-CoV-2, Autoimmune diseases, Rheumatic diseases, Autoantibodies